AbbVie IncABBV

ABBV current price
$199.50+30.42%

Capital at risk.

1W
+0.28%
1M
+2.60%
3M
-8.05%
6M
+9.81%
1Y
+30.42%
MAX
+305.65%
Calendar
event
Ex dividend date
15 Jan 2025
calendar_clock
Next Dividend Payment
14 Feb 2025
About AbbVie Inc
Ticker
info
ABBV
Trading on
info
NYSE
ISIN
info
US00287Y1091
Industry
info
Drug Manufacturers - General
Sector
info
Healthcare
CEO
info
Robert A. Michael
Headquarters
info
1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
Employees
info
50,000
Website
info
abbvie.com
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Metrics
BasicAdvanced
Market cap
info
$353B
P/E ratio
info
69.51
EPS
info
$2.87
Dividend Yield
info
3.29%
Beta
info
0.61
Forward P/E ratio
info
16.84
EBIDTA
info
$25.6B
Ex dividend date
info
2025-01-15
Price & volume
Market cap
info
$353B
Average daily volume
info
6.2M
90-day return
info
-8.05%
30-day return
info
2.60%
7-day return
info
0.28%
Dividends
Dividend per share
info
$6.20
Dividend yield
info
3.29%
Forward dividend per share
info
$6.56
Forward dividend yield
info
3.29%
Payout ratio
info
57.67%
Valuation
P/E ratio
info
69.51
Forward P/E
info
16.84
PEG ratio
info
0.47
Trailing P/E
info
69.51
Price to sales
info
6.35
Price to book
info
58.45
Earnings
EPS
info
$2.87
EPS estimate (current quarter)
info
$2.91
EPS estimate (next quarter)
info
$2.95
EBITDA
info
$25.6B
Revenues (TTM)
info
$55.5B
Revenues per share (TTM)
info
$31.40
Technicals
Beta
info
0.61
52-week High
info
$207.32
52-week Low
info
$131.48
50-day moving average
info
$194.58
200-day moving average
info
$178.81
Short ratio
info
3.56
Short %
info
0.92%
Management effectiveness
ROE (TTM)
info
56.41%
ROA (TTM)
info
7.72%
Profit margin
info
9.22%
Gross profit margin
info
$41.5B
Operating margin
info
28.93%
Growth
Quarterly earnings growth (YoY)
info
12.30%
Quarterly revenue growth (YoY)
info
3.80%
Share stats
Outstanding Shares
info
1.77B
Float
info
1.76B
Insiders %
info
0.09%
Institutions %
info
73.42%
Analyst Insights & forecasts
info

67% Buy

33% Hold

0% Sell

Based on information from 27 analysts.

Average price target

info
$211.24
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$2.79
$2.77
0.72%
Q4 • 23Beat
$2.31
$2.23
3.59%
Q1 • 24Beat
$2.65
$2.57
3.11%
Q2 • 24Beat
$3.00
$2.92
2.74%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$14.5B
$1.37B
9.47%
Q2 • 24
$14.5B
$1.56B
10.80%
Q3 • 24
0.01%
13.94%
13.96%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$142B
$135B
95.19%
Q2 • 24
$143B
$-6.82B
4.76%
Q3 • 24
1.05%
105.05%
105.00%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$2.27B
$-1.1B
$-6.1B
$2.03B
Q2 • 24
$5.45B
$-8.26B
$-3.07B
$5.88B
Q3 • 24
139.85%
649.18%
49.61%
189.70%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Greed

+1.5

0.56

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a AbbVie Inc share?
Collapse

AbbVie Inc shares are currently traded for $199.50 per share.

How many shares does AbbVie Inc have?
Collapse

AbbVie Inc currently has 1.77B shares.

Does AbbVie Inc pay dividends?
Collapse

Yes, AbbVie Inc does pay dividends.

What is AbbVie Inc 52 week high?
Collapse

AbbVie Inc 52 week high is $207.32.

What is AbbVie Inc 52 week low?
Collapse

AbbVie Inc 52 week low is $131.48.

What is the 200-day moving average of AbbVie Inc?
Collapse

AbbVie Inc 200-day moving average is $178.81.

Who is AbbVie Inc CEO?
Collapse

The CEO of AbbVie Inc is Robert A. Michael.

How many employees AbbVie Inc has?
Collapse

AbbVie Inc has 50,000 employees.

What is the market cap of AbbVie Inc?
Collapse

The market cap of AbbVie Inc is $353B.

What is the P/E of AbbVie Inc?
Collapse

The current P/E of AbbVie Inc is 69.51.

What is the EPS of AbbVie Inc?
Collapse

The EPS of AbbVie Inc is $2.87.

What is the PEG Ratio of AbbVie Inc?
Collapse

The PEG Ration of AbbVie Inc is 0.47.

What do analysts say about AbbVie Inc?
Collapse

According to the analysts AbbVie Inc is considered a buy.